Overview

Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression

Status:
Terminated
Trial end date:
2019-03-26
Target enrollment:
Participant gender:
Summary
This study is intended to evaluate the safety and potential efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion versus placebo in patients with Treatment Resistant Depression.
Phase:
Phase 1
Details
Lead Sponsor:
Joshua M Hare